Gamida Cell Ltd. announced the resignation of Chairman Robert I. Blum. The Board of Directors has elected Shawn Cline Tomasello Chairwoman, effective immediately. The Board also appointed Ms. Tomasello to the Board's Audit Committee, effective immediately.

Shawn Cline Tomasello joined Gamida Cell's Board of Directors in June 2019, bringing extensive experience in leading successful commercial activities at several pharmaceutical companies and providing key strategic guidance on company boards. Most recently, she served as Chief Commercial Officer of Kite Pharma, now part of Gilead Sciences, where she oversaw the global commercialization of Yescarta, the first approved CAR-T therapy for non-Hodgkin lymphoma, and was a key executive in the Kite/Gilead acquisition for $11.9 billion in August 2017. Prior to joining Kite, Ms. Tomasello was Chief Commercial Officer and had responsibility for medical affairs at Pharmacyclics.

While at Pharmacyclics, the company's market cap increased from $8 billion to $19 billion, and it was ultimately acquired by AbbVie for $21 billion. Ms. Tomasello has extensive strategic experience in building world-class organizations working across all relevant encompassing functions. She holds a bachelor's degree in marketing from the University of Cincinnati and an MBA from Murray State University and currently also serves on the public boards of AlloVir, TCR2 Therapeutics Inc. and 4D Molecular Therapeutics.

On March 15, 2023, Dr. Anat Cohen-Dayag submitted her resignation from the board of directors (the Board") of Gamida Cell Ltd. (the Company"), which resignation was effective immediately. Dr. Cohen-Dayag was a member of the Board's Nominating and Governance Committee and chairperson of the Board's Science and Technology Committee. On March 16, 2023, Dr. Naama Halevi Davidov submitted her resignation from the Board, which resignation was effective immediately.

Dr. Halevi Davidov was a member of the Board's Audit Committee. On March 17, 2023, Mr. Robert Blum submitted his resignation from the Board, which resignation was effective immediately. Mr. Blum was chairperson of the Board, chairperson of the Board's Nominating and Governance Committee, and a member of the Board's Compliance Committee.

On March 20, 2023, the Board appointed Mr. Ken Moch and Dr. Ivan Borrello to the Board's Nominating & Governance Committee, with Mr. Moch to serve as the chair of such committee. In addition, on March 20, 2023, the Board appointed Dr. Julian Adams to the Board's Compliance Committee.